IL-6, another abundant cytokine present both at tissue and systemic levels in PCa patients, limits NK cell anti-tumor activities, via STAT3 activation, by decreasing MICA/B and ULBPs NK cell-activating ligands, resulting in decrease NK cell killing capabilities. Here, STAT3 is linked to neoplasm.